-- Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. -- Total revenue remained
Gilead Sciences Inc.
-(GILD)
XLON:GILD
What to expect from Gilead Sciences Q3 earnings
Gilead Sciences (NASDAQ: GILD) is set to report its third-quarter earnings results on Thursday after the market closes. The biotechnology firm is
Gilead’s Q2 results beat estimates
Gilead Sciences Inc. (NYSE: GILD) beat market estimates for revenue and earnings in the second quarter of 2019. Shares were down 0.21%
Earnings preview: What to look for when Gilead reports Q2 results
Gilead Sciences Inc. (NYSE: GILD) is scheduled to report second quarter 2019 earnings results on Tuesday, July 30, after market close. Analysts
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them
CymaBay Therapeutics stock drops to 2-year low after bitter NASH study data
CymaBay Therapeutics (NASDAQ: CBAY) stock fell to a two-year low of $4.82 on Tuesday after disappointing nonalcoholic steatohepatitis (NASH) trial data. The
Intercept Pharmaceuticals reports mixed Q1 results
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related to NASH
Gilead Sciences tops Q1 earnings estimate, reiterates full-year outlook
Shares of Gilead Sciences (NASDAQ: GILD) gained 1.2% after the biotechnology firm reported first-quarter earnings of $1.76 per share, surpassing the street
Gilead Sciences earnings preview: What to expect in Q1
Gilead Sciences (NASDAQ: GILD) has tested its investors enough lately. The stock has increased just 2.5% in the year-to-date period, while its
Calendar: Earnings of Alphabet, Pfizer, Merck, Apple, Gilead on queue
Alphabet, Pfizer, Merck, Apple, Gilead Sciences, and more earnings are scheduled for the week between April 29 and May 3. Check out
What is NASH and which biotech firms are vying for the first-mover status
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver disorder is
Viking Therapeutics earnings preview: All eyes on NASH
Viking Therapeutics (VKTX) is scheduled to report fourth-quarter 2018 financial results on March 13, Wednesday, after the regular trading hours. The market
Intercept stock surges on positive data from liver fibrosis drug study
Intercept Pharmaceuticals (ICPT) had surged about 25% in the pre-market session on Tuesday after the biopharma company announced positive topline results from
Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump
Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results and a
Gilead Sciences swings to profit in Q4, but misses estimates
Gilead Sciences (GILD) swung to a profit in the fourth quarter from a loss last year, helped by a plunge in income
Earnings preview: HIV to drive topline growth for Gilead Sciences in Q4
Biotechnology company Gilead Sciences (GILD) is scheduled to report fourth-quarter earnings results after the closing bell on Monday, February 4. The company
Gilead names Daniel O’Day as Chairman and CEO
Gilead Sciences Inc. (GILD) has named Daniel O’Day as its new Chairman and Chief Executive Officer, effective March 1, 2019. O’Day comes